Ameriprise’s Astria Therapeutics ATXS Stock Holding History

Ameriprise’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,538	Closed	-$44K	–	3891
2021 Q1	$44K	Buy	+2,538	New	+$45.9K	﹤0.01%	3805

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ameriprise's ATXS Position: Q2 2021 in Review

Ameriprise sold out of Astria Therapeutics (ATXS) in Q2 2021, closing a stake of 2,538 shares — an estimated $44K sold.

Ameriprise first reported a position in ATXS in Q1 2021 and held it in 1 quarter. The position peaked at $44K in Q1 2021. 58 funds tracked by Wall St. Rank hold ATXS as of Q2 2021.

Ameriprise reported no remaining Astria Therapeutics position as of Q2 2021 after selling out during the quarter.
Ameriprise sold 2,538 Astria Therapeutics shares in Q2 2021, an estimated $44K.
Ameriprise first reported a position in Astria Therapeutics in Q1 2021 and held it in 1 quarter.
Ameriprise's Astria Therapeutics position peaked at $44K in Q1 2021.
58 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2021.

Based on Ameriprise's 13F filing for Q2 2021, filed 16 Aug 2021.